secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2022-09-23T23:59:59+00:00
Accession:  0001387131-22-009977
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.03, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences shifts focus to cardiac/oncology, cuts workforce 40%, gets $65M loan from chairman
--------------------------------------------------------------------------------

- Reduce workforce by ~40% (to 66 employees); $200K severance charges in Q3 2022.
- Kevin Danahy named CEO (was CCO); Darrin Uecker becomes CTO; Robert Duggan appointed Executive Chairman.
- Robert Duggan provides $65M unsecured loan at 5% interest, due March 20, 2024.
- Company evaluating dermatology partnerships; plans investor day within 60 days.
- Shift from dermatology to cardiovascular, oncology, and other healthcare verticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000138713122009977/0001387131-22-009977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000138713122009977/pulse-8k_092022.htm
  HTML page:      https://secwatch.observer/filing/0001387131-22-009977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer